Kinnate Biopharma
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Kinnate Biopharma generated cash of -$100,043,000, which is less than the previous year. Cash used in financing activities reached the amount of $1,325,000 last year. Net change in cash is therefore $2,012,000.
Cash Flow
| 2018 | -8.20M | 0 | 15.20M |
|---|---|---|---|
| 2019 | -10.52M | 0 | 79.98M |
| 2020 | -30.18M | -31.70M | 350.89M |
| 2021 | -71.06M | -180.57M | 36.23K |
| 2022 | -89.03M | -6.83M | 1.16K |
| 2023 | -100.04M | 100.73M | 1.32M |
KNTE Cash Flow Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 54.98M | 150.06M | 365.46M | 76.45M | 6.99M | 0 |
Operating activities | ||||||
Net income | -112.64M | -116.27M | -89.76M | -35.76M | -11.96M | -7.63M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 799K | 604K | 123K | 83K | 0 | 0 |
Stock-based compensation expense | 19.91M | 19.58M | 15.01M | 2.47M | 39K | 39K |
| Deferred income tax benefit | 19.91M | 19.58M | 15.01M | 2.47M | 39K | 39K |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 0 | 0 | 0 | 973K | -49K | 0 |
Inventories | 0 | 0 | 0 | -973K | 0 | 0 |
Accounts payable | -5.07M | 4.19M | 4.67M | 5.35M | 1.47M | 0 |
Cash generated by operating activities | -100.04M | -89.03M | -71.06M | -30.18M | -10.52M | -8.20M |
Investing activities | ||||||
Purchases Of Investments | -154.71M | -176.52M | -247.14M | -31.41M | 0 | 0 |
Investments In Property Plant And Equipment | 0 | -2.71M | -769K | -297K | 0 | 0 |
Acquisitions Net | -9.13M | 4.11K | 34.85M | 0 | 0 | 0 |
Cash generated by investing activities | 100.73M | -6.83M | -180.57M | -31.70M | 0 | 0 |
Financing activities | ||||||
Common Stock Issued | 1.32M | 0 | 0 | 253.31M | 79.98M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | -17K | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 1.32M | 1.16K | 36.23K | 350.89M | 79.98M | 15.20M |
Net Change In Cash | 2.01M | -94.70M | -215.40M | 289.00M | 69.45M | 6.99M |
Cash at end of period | 56.99M | 55.35M | 150.06M | 365.46M | 76.45M | 6.99M |
| Data source | Data source | Data source |